Evidence map›Paper›PMID 24876933›Full record

ReviewJournal of thoracic disease2014

Esophageal cancer: staging system and guidelines for staging and treatment.

Mark F Berry

Abstract readReview
In one paragraph

Review in Journal of thoracic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 4 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 4 syntheses or guidelines pooled it, 164 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Pooled it
  4. Non-surgical versus surgical treatment for oesophageal cancer.The Cochrane database of systematic reviews · 2016
    Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Assessment of methylated BCAT1 and IKZF1 circulating tumor DNA as a prognostic biomarker in esophagogastric adenocarcinomas.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mark F BerryDepartment of Surgery, Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Duke Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival of esophageal cancer is improving but remains poor. Esophageal cancer stage is based on depth of tumor invasion, involvement of regional lymph nodes, and the presence or absence of metastatic disease. Appropriate work-up is critical to identify accurate pre-treatment staging so that both under-treatment and unnecessary treatment is avoided. Treatment strategy should follow guideline recommendations, and generally should be developed after multidisciplinary evaluation.

Indexed as

Esophageal neoplasmsesophagectomyneoplasm staging

Identifiers

PMID24876933
PMCPMC4037413
OpenAlexW1938378379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.